PROJECT SYNOPSIS
Colorectal cancer (CRC) represents a significant proportion of malignant diseases. Interventions are often carried out during the latter stages of development, leading to low patient survival rates and poor quality of life. In 2022 a European Commission report stated that “colonoscopy-based screening has higher sensitivity than testing for blood in stool, but it is less acceptable to participants”. At the same time, effective methods to treat polyps in the colon are limited. Current approaches are often associated with unsafe oncological margins and high complication rates, requiring life-changing surgery. EndoTheranostics will usher in a new era for screening colonoscopy, advancing the frontiers of medical imaging and robotics. A tip- growing or eversion robot with a sleeve-like structure will be created to extend deep into hollow spaces while perceiving the environment through multimodal imaging and sensing. It will also act as a conduit to transfer miniaturised instruments to the remote site within the colon for diagnosis and therapy (theranostics). With these capabilities, the system will be able to offer: 1. painless colon cleansing in preparation for endoscopy; 2. real-time polyp detection and tissue characterisation through AI-assisted multimodal imaging; 3. effective removal of polyps by conveying a “miniature mobile operating chamber” equipped with microsurgical tools to the target through the lumen of the eversion robot. The unique technical and clinical challenges will be tackled by the PIs, each bringing complementary skills, backed by their institutions with wide expertise and exceptional facilities. The synergy and added value evident in this team will lead to breakthroughs not possible through independent research. The outcomes of EndoTheranostics will revolutionise the theranostics of CRC, impacting the quality of life of millions of individuals. Ultimately it will launch a new era for endoluminal intervention with applications beyond medicine.
Colorectal cancer (CRC) represents a significant proportion of malignant diseases. Interventions are often carried out during the latter stages of development, leading to low patient survival rates and poor quality of life. In 2022 a European Commission report stated that “colonoscopy-based screening has higher sensitivity than testing for blood in stool, but it is less acceptable to participants”. At the same time, effective methods to treat polyps in the colon are limited. Current approaches are often associated with unsafe oncological margins and high complication rates, requiring life-changing surgery. EndoTheranostics will usher in a new era for screening colonoscopy, advancing the frontiers of medical imaging and robotics. A tip- growing or eversion robot with a sleeve-like structure will be created to extend deep into hollow spaces while perceiving the environment through multimodal imaging and sensing. It will also act as a conduit to transfer miniaturised instruments to the remote site within the colon for diagnosis and therapy (theranostics). With these capabilities, the system will be able to offer: 1. painless colon cleansing in preparation for endoscopy; 2. real-time polyp detection and tissue characterisation through AI-assisted multimodal imaging; 3. effective removal of polyps by conveying a “miniature mobile operating chamber” equipped with microsurgical tools to the target through the lumen of the eversion robot. The unique technical and clinical challenges will be tackled by the PIs, each bringing complementary skills, backed by their institutions with wide expertise and exceptional facilities. The synergy and added value evident in this team will lead to breakthroughs not possible through independent research. The outcomes of EndoTheranostics will revolutionise the theranostics of CRC, impacting the quality of life of millions of individuals. Ultimately it will launch a new era for endoluminal intervention with applications beyond medicine.
